Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1995 Nov;96(5):2162–2169. doi: 10.1172/JCI118270

Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy.

H Yoshida 1, T Mitarai 1, T Kawamura 1, T Kitajima 1, Y Miyazaki 1, R Nagasawa 1, Y Kawaguchi 1, H Kubo 1, I Ichikawa 1, O Sakai 1
PMCID: PMC185865  PMID: 7593601

Abstract

Studies conducted over the last decade demonstrated variable therapeutic efficacy of angiotensin converting enzyme (ACE) inhibitor on the progression of glomerular diseases, including IgA nephropathy. In this study, among patients with biopsy-proven IgA nephropathy, 53 patients in whom creatinine clearance had been monitored over 5 yr were recruited for study. These patients were classified into two groups according to whether or not renal function had declined as determined by the slope of creatinine clearance against time: group 1 had stable renal function; group 2 had declining renal function (average: -6.7 +/- 1.3 ml/min/yr). 21 of 53 patients were treated with ACE inhibitor and followed for 48 wk. Gene polymorphism consisting of insertion (I) or deletion (D) of a 287-bp DNA fragment (presumed to be a silencer element) of the ACE gene was determined by PCR. 46 age-matched individuals without history of proteinuria were analyzed as controls. The DD genotype was significantly more frequent in group 2 (43%) than in controls (7%) or group 1 patients with stable renal function (16%). 48 wk after ACE inhibitor administration, proteinuria significantly decreased in patients with DD genotype but not in those with ID or II genotypes. The results indicate that deletion polymorphism in the ACE gene, particularly the homozygote DD, is a risk factor for progression to chronic renal failure in IgA nephropathy. Moreover, this deletion polymorphism predicts the therapeutic efficacy of ACE inhibition on proteinuria and, potentially, on progressive deterioration of renal function.

Full text

PDF
2162

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alamartine E., Sabatier J. C., Guerin C., Berliet J. M., Berthoux F. Prognostic factors in mesangial IgA glomerulonephritis: an extensive study with univariate and multivariate analyses. Am J Kidney Dis. 1991 Jul;18(1):12–19. doi: 10.1016/s0272-6386(12)80284-8. [DOI] [PubMed] [Google Scholar]
  2. Allon M., Pasque C. B., Rodriguez M. Acute effects of captopril and ibuprofen on proteinuria in patients with nephrosis. J Lab Clin Med. 1990 Oct;116(4):462–468. [PubMed] [Google Scholar]
  3. Anderson S., Rennke H. G., Brenner B. M. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest. 1986 Jun;77(6):1993–2000. doi: 10.1172/JCI112528. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Berger J. IgA glomerular deposits in renal disease. Transplant Proc. 1969 Dec;1(4):939–944. [PubMed] [Google Scholar]
  5. Beukhof J. R., Kardaun O., Schaafsma W., Poortema K., Donker A. J., Hoedemaeker P. J., van der Hem G. K. Toward individual prognosis of IgA nephropathy. Kidney Int. 1986 Feb;29(2):549–556. doi: 10.1038/ki.1986.33. [DOI] [PubMed] [Google Scholar]
  6. Björck S., Nyberg G., Mulec H., Granerus G., Herlitz H., Aurell M. Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. Br Med J (Clin Res Ed) 1986 Aug 23;293(6545):471–474. doi: 10.1136/bmj.293.6545.471. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bøhn M., Berge K. E., Bakken A., Erikssen J., Berg K. Insertion/deletion (I/D) polymorphism at the locus for angiotensin I-converting enzyme and myocardial infarction. Clin Genet. 1993 Dec;44(6):292–297. doi: 10.1111/j.1399-0004.1993.tb03903.x. [DOI] [PubMed] [Google Scholar]
  8. Bøhn M., Berge K. E., Bakken A., Erikssen J., Berg K. Insertion/deletion (I/D) polymorphism at the locus for angiotensin I-converting enzyme and parental history of myocardial infarction. Clin Genet. 1993 Dec;44(6):298–301. doi: 10.1111/j.1399-0004.1993.tb03904.x. [DOI] [PubMed] [Google Scholar]
  9. Cambien F., Poirier O., Lecerf L., Evans A., Cambou J. P., Arveiler D., Luc G., Bard J. M., Bara L., Ricard S. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 1992 Oct 15;359(6396):641–644. doi: 10.1038/359641a0. [DOI] [PubMed] [Google Scholar]
  10. Cattran D. C., Greenwood C., Ritchie S. Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin a nephropathy: a comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis. 1994 Feb;23(2):247–254. doi: 10.1016/s0272-6386(12)80980-2. [DOI] [PubMed] [Google Scholar]
  11. Clozel J. P., Kuhn H., Hefti F. Effects of chronic ACE inhibition on cardiac hypertrophy and coronary vascular reserve in spontaneously hypertensive rats with developed hypertension. J Hypertens. 1989 Apr;7(4):267–275. [PubMed] [Google Scholar]
  12. Costerousse O., Allegrini J., Lopez M., Alhenc-Gelas F. Angiotensin I-converting enzyme in human circulating mononuclear cells: genetic polymorphism of expression in T-lymphocytes. Biochem J. 1993 Feb 15;290(Pt 1):33–40. doi: 10.1042/bj2900033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. D'Amico G. Clinical features and natural history in adults with IgA nephropathy. Am J Kidney Dis. 1988 Nov;12(5):353–357. doi: 10.1016/s0272-6386(88)80023-4. [DOI] [PubMed] [Google Scholar]
  14. D'Amico G., Imbasciati E., Barbiano Di Belgioioso G., Bertoli S., Fogazzi G., Ferrario F., Fellin G., Ragni A., Colasanti G., Minetti L. Idiopathic IgA mesangial nephropathy. Clinical and histological study of 374 patients. Medicine (Baltimore) 1985 Jan;64(1):49–60. [PubMed] [Google Scholar]
  15. Docci D., Moscatelli G., Capponcini C., Baldrati L., Feletti C. Nephrotic-range proteinuria in a patient with high renin hypertension: effect of treatment with an ACE-inhibitor. Am J Nephrol. 1992;12(5):387–389. doi: 10.1159/000168479. [DOI] [PubMed] [Google Scholar]
  16. Doria A., Warram J. H., Krolewski A. S. Genetic predisposition to diabetic nephropathy. Evidence for a role of the angiotensin I--converting enzyme gene. Diabetes. 1994 May;43(5):690–695. doi: 10.2337/diab.43.5.690. [DOI] [PubMed] [Google Scholar]
  17. Higashimori K., Zhao Y., Higaki J., Kamitani A., Katsuya T., Nakura J., Miki T., Mikami H., Ogihara T. Association analysis of a polymorphism of the angiotensin converting enzyme gene with essential hypertension in the Japanese population. Biochem Biophys Res Commun. 1993 Mar 15;191(2):399–404. doi: 10.1006/bbrc.1993.1231. [DOI] [PubMed] [Google Scholar]
  18. Higashimori K., Zhao Y., Higaki J., Kamitani A., Katsuya T., Nakura J., Miki T., Mikami H., Ogihara T. Association analysis of a polymorphism of the angiotensin converting enzyme gene with essential hypertension in the Japanese population. Biochem Biophys Res Commun. 1993 Mar 15;191(2):399–404. doi: 10.1006/bbrc.1993.1231. [DOI] [PubMed] [Google Scholar]
  19. Hommel E., Parving H. H., Mathiesen E., Edsberg B., Damkjaer Nielsen M., Giese J. Effect of captopril on kidney function in insulin-dependent diabetic patients with nephropathy. Br Med J (Clin Res Ed) 1986 Aug 23;293(6545):467–470. doi: 10.1136/bmj.293.6545.467. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Hubert C., Houot A. M., Corvol P., Soubrier F. Structure of the angiotensin I-converting enzyme gene. Two alternate promoters correspond to evolutionary steps of a duplicated gene. J Biol Chem. 1991 Aug 15;266(23):15377–15383. [PubMed] [Google Scholar]
  21. Julian B. A., Waldo F. B., Rifai A., Mestecky J. IgA nephropathy, the most common glomerulonephritis worldwide. A neglected disease in the United States? Am J Med. 1988 Jan;84(1):129–132. doi: 10.1016/0002-9343(88)90019-8. [DOI] [PubMed] [Google Scholar]
  22. Kakinuma Y., Kawamura T., Bills T., Yoshioka T., Ichikawa I., Fogo A. Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure. Kidney Int. 1992 Jul;42(1):46–55. doi: 10.1038/ki.1992.259. [DOI] [PubMed] [Google Scholar]
  23. Kitajima T., Murakami M., Sakai O. Clinicopathological features in the Japanese patients with IgA nephropathy. Jpn J Med. 1983 Aug;22(3):219–222. doi: 10.2169/internalmedicine1962.22.219. [DOI] [PubMed] [Google Scholar]
  24. Klahr S., Schreiner G., Ichikawa I. The progression of renal disease. N Engl J Med. 1988 Jun 23;318(25):1657–1666. doi: 10.1056/NEJM198806233182505. [DOI] [PubMed] [Google Scholar]
  25. Lewis E. J., Hunsicker L. G., Bain R. P., Rohde R. D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993 Nov 11;329(20):1456–1462. doi: 10.1056/NEJM199311113292004. [DOI] [PubMed] [Google Scholar]
  26. Lindpaintner K., Pfeffer M. A., Kreutz R., Stampfer M. J., Grodstein F., LaMotte F., Buring J., Hennekens C. H. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med. 1995 Mar 16;332(11):706–711. doi: 10.1056/NEJM199503163321103. [DOI] [PubMed] [Google Scholar]
  27. Linz W., Schölkens B. A., Ganten D. Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exp Hypertens A. 1989;11(7):1325–1350. doi: 10.3109/10641968909038172. [DOI] [PubMed] [Google Scholar]
  28. Marian A. J., Yu Q. T., Workman R., Greve G., Roberts R. Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death. Lancet. 1993 Oct 30;342(8879):1085–1086. doi: 10.1016/0140-6736(93)92064-z. [DOI] [PubMed] [Google Scholar]
  29. Marre M., Bernadet P., Gallois Y., Savagner F., Guyene T. T., Hallab M., Cambien F., Passa P., Alhenc-Gelas F. Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Diabetes. 1994 Mar;43(3):384–388. doi: 10.2337/diab.43.3.384. [DOI] [PubMed] [Google Scholar]
  30. Nagy J., Trinn C., Deák G., Schmelzer M., Burger T. The role of the tubulointerstitial changes in the prognosis of IgA glomerulonephritis. Klin Wochenschr. 1984 Nov 15;62(22):1094–1096. doi: 10.1007/BF01711380. [DOI] [PubMed] [Google Scholar]
  31. Nicholls K. M., Fairley K. F., Dowling J. P., Kincaid-Smith P. The clinical course of mesangial IgA associated nephropathy in adults. Q J Med. 1984 Spring;53(210):227–250. [PubMed] [Google Scholar]
  32. Nomura H., Koni I., Michishita Y., Morise T., Takeda R. Angiotensin-converting enzyme gene polymorphism in haemodialysis patients. Lancet. 1994 Feb 19;343(8895):482–483. doi: 10.1016/s0140-6736(94)92728-6. [DOI] [PubMed] [Google Scholar]
  33. Okada K., Funai M., Kawakami K., Kagami S., Yano I., Kuroda Y. IgA nephropathy in Japanese children and adults: a comparative study of clinicopathological features. Am J Nephrol. 1990;10(3):191–197. doi: 10.1159/000168080. [DOI] [PubMed] [Google Scholar]
  34. Parving H. H., Hommel E., Smidt U. M. Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. BMJ. 1988 Oct 29;297(6656):1086–1091. doi: 10.1136/bmj.297.6656.1086. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Raynolds M. V., Bristow M. R., Bush E. W., Abraham W. T., Lowes B. D., Zisman L. S., Taft C. S., Perryman M. B. Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. Lancet. 1993 Oct 30;342(8879):1073–1075. doi: 10.1016/0140-6736(93)92061-w. [DOI] [PubMed] [Google Scholar]
  36. Rekola S., Bergstrand A., Bucht H. Deterioration rate in hypertensive IgA nephropathy: comparison of a converting enzyme inhibitor and beta-blocking agents. Nephron. 1991;59(1):57–60. doi: 10.1159/000186518. [DOI] [PubMed] [Google Scholar]
  37. Remuzzi A., Perticucci E., Ruggenenti P., Mosconi L., Limonta M., Remuzzi G. Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy. Kidney Int. 1991 Jun;39(6):1267–1273. doi: 10.1038/ki.1991.160. [DOI] [PubMed] [Google Scholar]
  38. Rigat B., Hubert C., Alhenc-Gelas F., Cambien F., Corvol P., Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990 Oct;86(4):1343–1346. doi: 10.1172/JCI114844. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Schmidt S., van Hooft I. M., Grobbee D. E., Ganten D., Ritz E. Polymorphism of the angiotensin I converting enzyme gene is apparently not related to high blood pressure: Dutch Hypertension and Offspring Study. J Hypertens. 1993 Apr;11(4):345–348. doi: 10.1097/00004872-199304000-00003. [DOI] [PubMed] [Google Scholar]
  40. Schunkert H., Hense H. W., Holmer S. R., Stender M., Perz S., Keil U., Lorell B. H., Riegger G. A. Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. N Engl J Med. 1994 Jun 9;330(23):1634–1638. doi: 10.1056/NEJM199406093302302. [DOI] [PubMed] [Google Scholar]
  41. Sektas M., Kaczorowski T., Podhajska A. J. Purification and properties of the MboII, a class-IIS restriction endonuclease. Nucleic Acids Res. 1992 Feb 11;20(3):433–438. doi: 10.1093/nar/20.3.433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Tiret L., Kee F., Poirier O., Nicaud V., Lecerf L., Evans A., Cambou J. P., Arveiler D., Luc G., Amouyel P. Deletion polymorphism in angiotensin-converting enzyme gene associated with parental history of myocardial infarction. Lancet. 1993 Apr 17;341(8851):991–992. doi: 10.1016/0140-6736(93)91075-w. [DOI] [PubMed] [Google Scholar]
  43. Tiret L., Rigat B., Visvikis S., Breda C., Corvol P., Cambien F., Soubrier F. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet. 1992 Jul;51(1):197–205. [PMC free article] [PubMed] [Google Scholar]
  44. Yoshikawa N., Ito H., Nakamura H. Prognostic indicators in childhood IgA nephropathy. Nephron. 1992;60(1):60–67. doi: 10.1159/000186706. [DOI] [PubMed] [Google Scholar]
  45. Zee R. Y., Lou Y. K., Griffiths L. R., Morris B. J. Association of a polymorphism of the angiotensin I-converting enzyme gene with essential hypertension. Biochem Biophys Res Commun. 1992 Apr 15;184(1):9–15. doi: 10.1016/0006-291x(92)91150-o. [DOI] [PubMed] [Google Scholar]
  46. de Caestecker M. P., Bottomley M., Telfer B. A., Hutchinson I. V., Vose B. M., Ballardie F. W. Detection of abnormal peripheral blood mononuclear cell cytokine networks in human IgA nephropathy. Kidney Int. 1993 Dec;44(6):1298–1308. doi: 10.1038/ki.1993.382. [DOI] [PubMed] [Google Scholar]
  47. ter Wee P. M., Epstein M. Angiotensin-converting enzyme inhibitors and progression of nondiabetic chronic renal disease. Arch Intern Med. 1993 Aug 9;153(15):1749–1759. doi: 10.1001/archinte.153.15.1749. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES